Survival analysis of patients with AML with or without DNMT3A mutations in distinct AML subgroups. Survival analyses were performed on the AML patient cohort < 60 years of age and from which the APLs were excluded. (A) OS of patients with AML, excluding patients with CEBPA^DM (n = 392). (B) OS of patients with AML without FLT3^ITD and without NPM1 mutations (FLT3^wild-type/NPM1^wild-type; n = 235). (C) OS of patients with AML without FLT3^ITD, NPM1 mutations, and CEBPA^DM (FLT3^wild-type/NPM1^wild-type/CEBPA^wild-type; n = 215). (D) OS of patients with AML without FLT3^ITD, NPM1, IDH1, and IDH2 mutations (FLT3^wild-type/NPM1^wild-type/IDH1^wild-type/IDH2^wild-type; n = 203). (E) OS of patients with cytogenetically intermediate-risk AML without FLT3^ITD and without NPM1 mutations (FLT3^wild-type/NPM1^wild-type; n = 117). (F) OS of patients with cytogenetically intermediate-risk AML without FLT3^ITD, NPM1 mutations, and CEBPA^DM (FLT3^wild-type/NPM1^wild-type/CEBPA^wild-type; n = 98).